Skip to content
    ELV
    Earnings call· Mar 2025(Q1 FY25)

    Elevance Health Q1 FY25 earnings call ELV

    Apr 22, 2025 Source

    Executive summary

    Elevance Health Q1 FY25 — Strong Start with Reaffirmed Guidance

    Elevance Health delivered a strong start to FY25, with Q1 results aligning with expectations despite an elevated trend environment. The company reaffirmed its full-year adjusted EPS guidance, emphasizing disciplined execution and strategic investments in Carelon and integrated offerings. Management highlighted proactive engagement with partners and a focus on whole-person health to drive better outcomes and manage costs, particularly in Medicaid and Medicare Advantage.

    Highlights

    5

    • Adjusted diluted EPS grew over 10% year-over-year to $11.97, reflecting disciplined execution.

    • Carelon's operating gain grew 34% to $1.1 billion, driven by pharmacy volumes and risk-based capabilities.

    • Patient advocacy solutions supported over 6 million members with a 95% satisfaction rate.

    • HealthOS now supports over 88,000 care providers and 1,200 provider organizations.

    • Operating cash flow is expected to reach approximately $8 billion for the full year, despite Q1 timing impacts.

    Concerns

    3

    • Individual ACA membership effectuation rates are tracking below initial expectations, leading to projected mid-single-digit attrition in early Q2.

    • Consolidated benefit expense ratio increased 80 basis points year-over-year to 86.4% due to higher cost trend in Medicaid.

    • Flu-driven costs in Q1 came in modestly above expectations, impacting the benefit expense ratio by 15 to 20 basis points.

    Guidance & targets

    8
    CategoryTargetConfidence
    Adjusted diluted EPS
    $34.15 to $34.85
    high materiality
    High
    Adjusted EPS seasonality
    More than 60% in the first half of the year
    medium materiality
    High
    Operating cash flow
    Approximately $8 billion
    high materiality
    High
    Days in claims payable (DCP)
    Trend towards the low 40s
    low materiality
    Medium
    Individual ACA membership attrition
    Mid-single-digit percent range
    medium materiality
    High
    Individual ACA membership
    4.9 million to 5 million members
    medium materiality
    High
    Carelon Services growth
    At least 50%
    medium materiality
    High
    Medicaid margins
    Stabilization early in the year, improvements in the latter half
    high materiality
    Medium

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Health Benefits
    Operating gain declined slightly on higher Medicaid costs, partly offset by operating efficiencies.
    		———$2.2 billion
    Carelon
    Operating gain grew driven by growth in pharmacy volumes and improved performance of deployed risk-based capabilities.
    		—34%—$1.1 billion

    Operational metrics

    16
    GAAP diluted EPS
    $9.61
    Q1 FY25

    Reported on Form 8-K filing.

    Adjusted diluted EPS
    $11.97Over 10% year-over-year growth
    Q1 FY25

    Reflecting resilience and disciplined execution.

    Medical members
    45.8 millionUp 99,000 from year-end
    Q1 FY25

    Driven primarily by targeted expansion and better-than-expected retention rates in Medicare Advantage.

    Operating revenue
    $48.8 billionOver 15% increase
    Q1 FY25

    Principally driven by higher premium yields, growth in Medicare Advantage and Individual ACA membership, and CarelonRx product revenue, plus contributions from recent acquisitions.

    Consolidated benefit expense ratio
    86.4%Increase of 80 basis points year-over-year
    Q1 FY25

    Overall utilization patterns remain elevated but consistent with full year guidance assumptions.

    Adjusted operating expense ratio
    10.7%60 basis points improvement
    Q1 FY25

    Reflecting disciplined expense management and thoughtful prioritization of strategic investments.

    Net investment income
    Exceeded expectations
    Q1 FY25

    Factors driving outperformance were incorporated in full year guidance, with earlier timing than anticipated.

    Debt-to-capital ratio
    Approximately 41%
    Q1 FY25

    Preserving flexibility for strategic investments and future capital deployment.

    Days in claims payable (DCP)
    44 daysIncrease of 0.5 days sequentially
    As of March 31

    Reflects consistent and prudent approach to reserving.

    Share repurchases
    $880 million
    Q1 FY25

    Demonstrates confidence in intrinsic value of shares, pacing opportunistically.

    Patient advocacy solutions members supported
    Over 6 million
    Q1 FY25

    Delivering personalized guidance to navigate benefits, manage chronic conditions, and access behavioral health services.

    HealthOS care providers supported
    More than 88,000
    Q1 FY25

    Integrating clinical data and insights into provider workflows, enabling real-time decision-making and seamless prior authorizations.

    Value-based oncology PMPM savings
    Nearly $100
    Per member per month

    Driven by the value-based care model across medical and pharmacy, highlighting the impact of the whole health approach.

    Individual ACA membership growth
    Approximately 11%Sequentially
    Q1 FY25

    Despite lower effectuation rates tracking below initial expectations.

    Flu-driven costs impact on benefit expense ratio
    Between 15 and 20 basis points
    Q1 FY25

    Modestly above expectations, but severity was in line with assumptions and moderated as the quarter closed.

    Group MA enrollment percentage
    About 15%
    Q1 FY25

    Utilization patterns in group MA do not indicate meaningful acceleration in cost trend.

    Industry KPIs

    7
    MetricValueDetails
    Utilization trendsElevated
    Medical loss care ratio86.4%%
    Pharmacy scripts specialtyGrowth
    Membership covered lives by line45.8 millionmembers
    Segment revenue operating income$1.1 billionUSD
    Adjusted EPS EBITDA leverage guidance$34.15 to $34.85USD
    Medical cost trend vs pricing assumptionElevated

    Deals & partnerships

    2
    CareBridgeStrengthening capabilities in home and community-based services.

    Completed at the end of last year, integrating offerings into Medicaid and duals platforms to deliver high-touch in-home support and avoid ER visits.

    Centers Plan for Healthy LivingExpanding whole health approach in New York.

    Will expand the whole health approach to deliver improved care for members and greater value for the state of New York.

    Risks & headwinds

    4
    Elevated trend environmentQ1 FY25, ongoing

    Consolidated benefit expense ratio increased 80 bps YoY to 86.4%; flu-driven costs impacted MLR by 15-20 bps.

    Mitigation: Disciplined operations, proactive engagement with partners, accurate capture of clinical conditions, and strategic investments in value-based care models.

    Lower Individual ACA effectuation ratesEarly Q2 FY25

    Projected mid-single-digit percent membership attrition in early Q2.

    Mitigation: Revised membership assumptions factored into reaffirmed 2025 EPS guidance; expected stabilization of ACA base after Q2 attrition.

    Medicaid cost trendOngoing, particularly H1 FY25

    Trends remain elevated, contributing to YoY increase in benefit expense ratio.

    Mitigation: Ongoing constructive discussions with state partners for rate alignment, with January and April renewals in line with expectations; recovery in margins expected in H2 FY25 as rate updates materialize.

    V28 risk model changesFY25

    Changes to how Medicare Advantage plans receive funding based on members' clinical and demographic profiles.

    Mitigation: Changes were anticipated and incorporated into 2025 planning and pricing; disciplined approach to benefit design and coding; focus on accurately documenting member conditions.

    What to watch in Q2 FY25

    4

    Individual ACA membership stabilization

    After early Q2 FY25
    CurrentMid-single-digit percent attrition projected in early Q2
    TargetStabilization of ACA membership base

    Why it matters

    This will confirm the company's revised membership assumptions and the impact on full-year profitability, which is already factored into guidance.

    Given the 90-day grace period has now ended, we do project membership attrition in the mid-single-digit percent range in early Q2, after which we'll anticipate our membership or ACA membership base will stabilize for 2025.

    Q&A highlights

    6

    Seeking clarity on Medicare Advantage trends, particularly group MA and IRA impact, and whether Q1 utilization provides sufficient visibility for the full year.

    Management stated that Medicare costs remain elevated but manageable and consistent with expectations, with no material change from prior commentary. Flu and respiratory illnesses caused slightly higher utilization early in Q1 but moderated. They are closely tracking claims data and remain comfortable with the trend environment.

    “Medicare costs overall remain elevated but manageable to start the year, very consistent with our fourth quarter experience and very much in line with our expectations for the first quarter. Effectively, nothing has materially changed with respect to our prior commentary.”

    asked by A.J. Rice · answered by Mark Kaye

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Investments in Patient Advocacy and Digital Platforms

    Elevance Health continues to invest in transforming the healthcare experience. Patient advocacy solutions supported over 6 million members in Q1, achieving a 95% satisfaction rate by providing personalized guidance for benefits, chronic conditions, and behavioral health. The HealthOS digital platform has expanded its reach, now supporting more than 88,000 care providers and over 1,200 provider organizations, facilitating real-time decision-making and streamlining prior authorizations. The company has also eliminated prior authorization requirements for over 400 outpatient procedures for high-performing providers to reduce administrative burden.

    02

    Carelon's Expanding Role and Strategic Acquisitions

    Carelon services continue to be a strategic growth engine, demonstrating strong internal and external expansion. In Q1, Carelon launched new post-acute and behavioral health contracts with external health plan clients, reinforcing its scalable platform for whole-person care. The acquisition of CareBridge, completed at the end of last year, strengthens capabilities in home and community-based services, integrating into Medicaid and duals platforms to deliver high-touch in-home support and avoid ER visits. These efforts have driven nearly $100 in per member per month savings across medical and pharmacy.

    03

    Medicaid and Medicare Advantage Performance

    Medicaid performance is progressing with rate alignment, with April adjustments meeting expectations and early discussions underway for July cohorts. The long-term care model in Medicaid is delivering better outcomes at lower costs by integrating home-based services and behavioral health. In Medicare Advantage, performance was consistent with expectations, with strong retention and targeted, disciplined growth supporting margin and membership sustainability. The company remains confident in the long-term outlook for MA, noting that stronger retention leads to better care coordination and lower overall spending.

    04

    Individual ACA Membership Dynamics

    While Individual ACA membership grew approximately 11% sequentially in Q1, effectuation rates on renewing members are tracking below initial expectations. This is partly attributed to a surge in passive renewals among individuals transitioning from Medicaid. The company projects a mid-single-digit percentage attrition in early Q2, after which the ACA membership base is expected to stabilize for 2025, with commercial risk-based membership ending the year in the range of 4.9 million to 5 million members. These revised assumptions are factored into the reaffirmed 2025 EPS guidance.

    05

    Utilization Trends and Part D Seasonality

    Overall utilization patterns in the Health Benefits segment remain elevated but consistent with full-year guidance assumptions. Flu and respiratory illnesses caused slightly higher utilization in Q1, impacting the benefit expense ratio by 15-20 basis points, but moderated as the quarter closed. Changes from the Inflation Reduction Act (IRA) have reversed the usual quarterly seasonality pattern for Part D, resulting in stronger financial performance in earlier quarters and lower margins later in the year. This new seasonality more closely resembles the broader medical benefits business.

    AI-generated summary of the company’s earnings call. Not investment advice.